USPH Earnings

USPH reported its FY2025Q4 earnings on 2026-02-26, showcasing a revenue of 0.00 against an estimate of 198.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.67 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following USPH's FY2025Q4 earnings announcement on 2026-02-26, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, USPH's stock price tends to shift by an average of +0.56% in the 10 days leading up to earnings and +0.19% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate USPH’s annual revenue to reach 200.00M, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.57% and EPS estimates Revise Downward by -2.29% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between USPH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.57%, while EPS estimates moved Revise Downward by -2.29% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, USPH's stock price typically moves by +0.56% in the 10 days before its earnings and +0.19% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.00 and revenue of 200.00M.

The earnings call summary and Q&A indicate positive sentiment due to increased EBITDA guidance, strong growth in the injury prevention segment, and favorable financial metrics. The prioritization of acquisitions over buybacks, efficient recruitment strategies, and sustainable growth in key segments further bolster this outlook. While there are some uncertainties, such as the Medicare rate impact, the overall sentiment remains positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks, considering the company's small market cap.